Astellas Pharma (ALPMF) Income Statement
Astellas Pharma Income Statement
Last quarter (Q2 2026), Astellas Pharma's total revenue was $524.32B, a decrease of 2.53% from the same quarter last year. In Q2, Astellas Pharma's net income was $79.21B. See Astellas Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| $ 1.91T | $ 2.14T | $ 1.60T | $ 1.52T | $ 1.30T | |
| $ 1.56T | $ 1.59T | $ 1.31T | $ 1.23T | $ 1.04T | |
| $ 1.31T | $ 1.18T | $ 1.13T | $ 944.84B | $ 823.13B | |
| Depreciation and Amortization | $ 199.13B | $ 194.59B | $ 157.84B | $ 105.74B | $ 79.68B |
| $ 462.67B | $ 585.25B | $ 282.45B | $ 337.39B | $ 297.83B | |
| $ 255.67B | $ 419.70B | $ 178.07B | $ 285.43B | $ 220.02B | |
| $ -224.44B | $ -43.11B | $ -153.10B | $ -153.07B | $ -63.13B | |
| $ 31.24B | $ 376.59B | $ 24.97B | $ 132.36B | $ 156.89B | |
| $ 50.75B | $ 291.54B | $ 17.05B | $ 98.71B | $ 124.09B | |
| Per Share Metrics | |||||
| Basic EPS | $ 28.35 | $ 162.77 | $ 9.50 | $ 54.24 | $ 67.08 |
| Diluted EPS | $ 28.24 | $ 162.22 | $ 9.47 | $ 54.09 | $ 67.05 |
| Weighted Average Shares Outstanding | 1.79B | 1.79B | 1.79B | 1.82B | 1.85B |
| Weighted Average Shares Outstanding (Diluted) | 1.80B | 1.80B | 1.80B | 1.83B | 1.85B |
Currency in JPY